Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research, Real-world evidence
Method This is a retrospective single-center study aimed at evaluating the efficacy and safety of SEL combined with RUX regimen in RUX-resistant MF patients. The study included 21 MF patients with a poor response to RUX: 12 with PMF, 4 with post-PV MF, and 5 with post-ET MF. Patients received SEL at 20 mg, 40 mg, or 60 mg QW plus RUX (dosage determined by the investigator).
Result The median age is 56 (range, 37-71) years and the median duration of previous RUX treatment is 11.3 (6-39) months. 47.6% of patients had peripheral blood blasts of 1-9%. 16 (76.2%) patients harbored JAK2 mutations, 2 (9.5%) patients CALR mutations and 1 (5%) patient MPL mutations. All patients had splenomegaly, and 8 (38.1%) were transfusion-dependent. According to the DIPSS risk score, 11 patients (52.4%) were classified as high-risk, 5 (23.8%) as intermediate-2 risk, and 5 (23.8%) as unknown risk. Spleen size reduced in 16 (76.2%) patients with a median response time of 2.3 (1-3) months. Three patients underwent bridging to transplantation and are currently surviving with good recovery. Peripheral blood blasts decreased in 10 (47.6%) patients after one month of treatment. The most common adverse events during treatment were gastrointestinal reactions and cytopenias.
Conclusion The combination of SEL and RUX showed promising efficacy and manageable safety profile in RUX-resistant patients with myelofibrosis.
Keyword Selinexor; ruxolitinib; ruxolitinib-resistant; myelofibrosis
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts